Who is sponsoring NCT03664167?

NCT03664167 is sponsored by Henning Bliddal.

What condition does NCT03664167 study?

NCT03664167 studies Gout, Arthritis, Obesity.

Is NCT03664167 still recruiting?

NCT03664167 is currently completed. Last updated 24 June 2021.

Last reviewed 2021-06-24 · How we verify

NCT03664167

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Weight Loss for Obese Individuals With Gout

Completed NA Last updated 24 June 2021

What this trial tests

NA trial testing intensive weight loss diet, with Cambridge weightplan products, and visits to a dietician. in Gout, Arthritis, Obesity in 60 participants. Completed in 1 November 2019.

Timeline

1 December 2018

Primary endpoint
1 November 2019

1 November 2019

Quick facts

Lead sponsor	Henning Bliddal
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 December 2018
Primary completion	1 November 2019
Estimated completion	1 November 2019
Sites	1 location across Denmark

Drugs / interventions tested

intensive weight loss diet, with Cambridge weightplan products, and visits to a dietician.

Conditions studied

Gout, Arthritis, Obesity — all drugs for Gout, Arthritis, Obesity →

Sponsor

Henning Bliddal

Who can join

18 and older, any sex, with Gout, Arthritis, Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates effect of weight loss in a group of obese patients with gouty arthritis. The study is a randomised group trial where half the patients receive intensive weight loss in the form of meal replacement from Cambridge as well as supervision from a clinical dietician and the other half get usual care.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of Diet and Dietary Supplements on Gout-Related Outcomes: A Systematic Review of Randomised Controlled Trials.
Pardali EC, Gkouvi A, Nasiou K, Cholevas C, et al · · 2025 · PMID 41647273 · DOI 10.31138/mjr.010725.era

Verify or expand the search:

Other Henning Bliddal trials

Trials by the same sponsor.

NCT04601883 — Colchicine as Treatment for People With Hand Osteoarthritis · Phase 4 · completed
NCT04585113 — Diagnostic Accuracy of Dual-energy CT · completed
NCT04373798 — C-reactive Protein Levels Among Individuals With COVID-19 · completed
NCT03060421 — Evaluation of the Safety of Intraarticular Aquamid Reconstruction Injection for Knee Osteoarthritis in Humans · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03664167 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Henning Bliddal
Last refreshed: 24 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03664167.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing